UBS Group
APUS

UBS Group’s Apimeds Pharmaceuticals US APUS Stock Holding History

UBS Group’s Portfolio APUS Stock Details APUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6K Buy
1,182
+763
+182% +$10.4K ﹤0.01% 8542
2026
Q1 		$7.49K Buy
419
+361
+622% +$5.81K ﹤0.01% 8573
2025
Q4 		$954 Buy
+58
New +$1.24K ﹤0.01% 9754

Other funds holding APUS

HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.43B AUM 37.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group's APUS Position: Q2 2026 in Review

UBS Group increased its Apimeds Pharmaceuticals US (APUS) stake by 182% in Q2 2026, buying an estimated $10.4K and bringing the position to 1,182 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #8542.

UBS Group first reported a position in APUS in Q4 2025 and has held it in 3 quarters since. 7 funds tracked by Wall St. Rank hold APUS as of Q2 2026.

  • UBS Group held 1,182 shares of Apimeds Pharmaceuticals US worth $10.6K as of Q2 2026.
  • UBS Group bought 763 Apimeds Pharmaceuticals US shares in Q2 2026, an estimated $10.4K.
  • Apimeds Pharmaceuticals US made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8542 holding.
  • UBS Group first reported a position in Apimeds Pharmaceuticals US in Q4 2025 and has held it in 3 quarters since.
  • 7 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.